PHAT Stock Analysis: Buy, Sell, or Hold?
PHAT - Phathom Pharmaceuticals, Inc. Common Stock
$10.92
-1.70 (-13.44%)
▼
5d:
-4.09%
30d:
+11.15%
90d:
-13.58%
BUY
HIGH Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 06, 2026
22d
Smart Money Accumulation
None View Scanner →
Strength: 6.5/10
Get Alerted When PHAT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called PHAT this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PHAT shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: PHAT shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$15.12
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$9.39
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PHAT is currently trading at $10.91, which is considered fair relative to its 30-day fair value range of $10.10 to $11.49. The stock's valuation (Forward PE: 7.6) is in line with its historical norms (7.5). At these levels, the market is pricing in 0.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PHAT is in a uptrend. Immediate support is located at $10.34, while resistance sits at $12.64. Short-term momentum is weak, with the stock down 13.4% recently.
Market Sentiment: PHAT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $23.70 (+117.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PHAT is in a uptrend. Immediate support is located at $10.34, while resistance sits at $12.64. Short-term momentum is weak, with the stock down 13.4% recently.
Market Sentiment: PHAT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $23.70 (+117.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$10.10 -
$11.49
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-13.4%)
- BULLISH: Trading 117.1% below Wall St target ($23.70)
- NEUTRAL: Market pricing in 0.2% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$10.10 -
$11.49
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$10.34
Resistance Level
$12.64
Current Trend
Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.59
Wall Street Target
$23.70
(+117.1%)
Revenue Growth (YoY)
104.4%
Profit Margin
-76.8%
Valuation Premium vs History
+0.2% premium
PE vs Historical
7.6 vs 7.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.2%
(market-implied from PE analysis)
1-Year Target
$10.94
(+0%)
2-Year Target
$10.96
(+0%)
3-Year Target
$10.98
(+1%)
3-Yr Target (if PE normalizes)
(PE: 8→8)
PE COMPRESSION
$10.86
(-1%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: July 14, 2026 4:41 AM ET
Data refreshes hourly during market hours. Next update: 5:41 AM
Data refreshes hourly during market hours. Next update: 5:41 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 64 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 45 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$277 | 51 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
Advanced PHAT Option Strategies
Professional options setups generated by AI based on today's PHAT price and gamma walls.
